Vertex Pharmaceuticals Incorporated (VRTX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 1.43B | 498M | 1.24B | 1.07B | 818.9M | 584.6M | 1.37B | -3.75B | 1.31B | 234.6M | 1.27B | 1.13B |
| Operating CF Margin % | 47.81% | 15.43% | 40.35% | 36.2% | 29.56% | 20.08% | 49.42% | -141.88% | 48.62% | 9.32% | 51.07% | 45.5% |
| Operating CF Growth % | 74.39% | -14.81% | -9.37% | 128.59% | -37.33% | 149.19% | 7.99% | -430.89% | 45.19% | -78.25% | 32.75% | -0.47% |
| Net Income | 1.03B | 1.19B | 1.08B | 1.03B | 646.3M | 913M | 1.05B | -3.59B | 1.1B | 968.8M | 1.04B | 915.7M |
| Depreciation & Amortization | 55.9M | 55.7M | 54M | 51.7M | 48.4M | 46.5M | 53.2M | 54M | 53.5M | 59M | 42.1M | 41.4M |
| Stock-Based Compensation | 166.4M | 157.6M | 194.9M | 167.3M | 166.1M | 167.8M | 184.6M | 154.2M | 191.9M | 208.6M | 130.9M | 119.3M |
| Deferred Taxes | -65.3M | 30.5M | -235.9M | -113.8M | -191.6M | 51.6M | -123.3M | -118.8M | -158.3M | -131M | -115.5M | -176.6M |
| Other Non-Cash Items | -5M | 10.9M | -4.1M | 67.4M | 418.2M | -34.1M | 52.4M | -8M | -9.4M | -31.9M | -13.3M | -10.8M |
| Working Capital Changes | 244.7M | -947.8M | 149.6M | -132.4M | -268.5M | -560.2M | 157.5M | -241.4M | 129.3M | -838.9M | 188.9M | 245.4M |
| Change in Receivables | 39.8M | -99.4M | -59.9M | -18.4M | -169.6M | 69M | -51.8M | 135.1M | -251.6M | 15.4M | -6.1M | -2.9M |
| Change in Inventory | -97.7M | -77.4M | -131.1M | -148.6M | -167.1M | -147.5M | -182.5M | -107.2M | -80.1M | -70M | -97.5M | -72.8M |
| Change in Payables | 35.6M | 38.3M | -35.3M | 7.6M | 26.2M | 8.4M | 66.1M | -25.1M | 100K | -31.8M | 9.2M | 35.6M |
| Cash from Investing | -431.9M | -288.1M | -117M | -484.5M | -55.8M | -821.9M | -348M | -463.7M | -2.14B | -886.5M | -117.7M | -303.9M |
| Capital Expenditures | -133.4M | -149.4M | -101.8M | -145.7M | -40.7M | -92.6M | -67.7M | -69M | -68.4M | -58.1M | -40.6M | -59.6M |
| CapEx % of Revenue | 4.47% | 4.63% | 3.31% | 4.91% | 1.47% | 3.18% | 2.44% | 2.61% | 2.55% | 2.31% | 1.63% | 2.39% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -15.9M | 800K | -4.3M | -5.3M | -30.9M | -266.1M | -22.7M | -180M | -58M | -1.1M | -29.9M |
| Cash from Financing | -538.8M | -77.2M | -1.15B | -349.2M | -680.4M | -391.3M | -387.5M | -358.6M | -357.5M | -119.8M | -165M | 17.3M |
| Debt Issued (Net) | 0 | -1.4M | -1.4M | -1.3M | -1.3M | -1.3M | -5.4M | -13.7M | -13.2M | -12M | -11.3M | -11M |
| Equity Issued (Net) | -309.9M | -76.9M | -1.06B | -342.7M | -409.4M | -383.6M | -299.3M | -265.3M | -114.3M | -103.1M | -101.6M | 30.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -336.9M | -130.9M | -1.07B | -391.8M | -426.1M | -417.9M | -307.7M | -320.3M | -131.2M | -149.5M | -117M | -28.3M |
| Other Financing | -228.9M | 1.1M | -89.9M | -5.2M | -269.7M | -6.4M | -82.8M | -79.6M | -230M | -4.7M | -52.1M | -2M |
| Net Change in Cash | 417.1M | 140M | -34.2M | 296.6M | 113.2M | -675.9M | 657.1M | -4.58B | -1.2B | -744.3M | 963.2M | 857.8M |
| Free Cash Flow | 1.29B | 348.6M | 1.14B | 927.4M | 778.2M | 492M | 1.3B | -3.83B | 1.06B | 176.5M | 1.23B | 1.07B |
| FCF Margin % | 43.35% | 10.8% | 37.04% | 31.28% | 28.09% | 16.9% | 46.98% | -144.78% | 39.38% | 7.01% | 49.44% | 43.11% |
| FCF Growth % | 66.37% | -29.15% | -12.48% | 124.21% | -26.46% | 178.75% | 6.05% | -456.37% | 23.36% | -83.11% | 36.23% | -1.08% |
| FCF per Share | 5.05 | 1.36 | 4.42 | 3.58 | 3.00 | 1.89 | 4.99 | -14.84 | 4.05 | 0.68 | 4.71 | 4.13 |
| FCF Conversion (FCF/Net Income) | 1.38x | 0.42x | 1.15x | 1.04x | 1.27x | 0.64x | 1.31x | 1.04x | 1.19x | 0.24x | 1.23x | 1.24x |
| Interest Paid | 3.2M | 3M | 3.2M | 3.5M | 2.7M | 2.7M | 8.1M | 9.7M | 10M | 10.5M | 10.6M | 10.9M |
| Taxes Paid | 82.3M | 389.4M | 479.6M | 513.3M | 184.4M | 271.8M | 278.5M | 497M | 34.8M | 758.2M | 300.4M | 498.4M |